At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
In Brief
A Phase 2 clinical trial evaluating Cyclophosphamide, Cytarabine, and 8 other interventions for Recurrent B Acute Lymphoblastic Leukemia and 3 related conditions. Terminated early, enrolled 53 participants across 1 site.
Signals
Detailed Summary
This phase I/II trial studies the side effects and best dose of venetoclax and how well it works in combination with low-intensity chemotherapy in patients with B- or T-cell acute lymphoblastic leukemia that has not responded to treatment or that has come back. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, including vincristine, cyclophosphamide, dexamethasone, rituximab, methotrexate, and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax with low-intensity chemotherapy may work better in treating patient with B- or T-cell acute lymphoblastic leukemia.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV or PO
Given IV
Given IV
Given IV
Given PO
Given IV
Given PO
Given IV